International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Feb 2007
Multicenter StudyThe role of palliative radiation therapy in symptomatic locally advanced gastric cancer.
To review the outcome of palliative radiotherapy (RT) alone in patients with symptomatic locally advanced or recurrent gastric cancer. ⋯ External beam RT alone is an effective and well tolerated modality in the local palliation of gastric cancer, with palliation lasting the majority of patients' lives.
-
Int. J. Radiat. Oncol. Biol. Phys. · Feb 2007
Multicenter StudyEscalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression.
In many centers worldwide, radiotherapy for metastatic spinal cord compression (MSCC) is performed with 30 Gy in 10 fractions. This study investigated the potential benefit of dose escalation. ⋯ Escalation of the radiation dose to >30 Gy in 10 fractions did not improve the outcomes in terms of motor function, local control, or survival but did increase the treatment time for these frequently debilitated patients. Therefore, doses >30 Gy in 10 fractions are not recommended.
-
Int. J. Radiat. Oncol. Biol. Phys. · Feb 2007
Ototoxicity after radiotherapy for head and neck tumors.
To investigate the incidence of radiation-induced ototoxicity according to the total dose delivered to specific parts of the auditory system, fractionation, and chemotherapy. ⋯ Radiotherapy toxicity was observed in all parts of the auditory system with median doses for incidence varying between 60 Gy to 66 Gy. Total dose to organ seems to be a significant factor though fractionation and chemo-radiation may contribute to ototoxicities.
-
Int. J. Radiat. Oncol. Biol. Phys. · Feb 2007
Multicenter StudyPhase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
Preoperative paclitaxel-based chemoradiotherapy may improve the response rates and survival in patients with localized esophageal cancer. We evaluated paclitaxel-based induction chemoradiotherapy in patients with localized esophageal cancer to determine its feasibility, clinical response, pathologic response, and overall survival. ⋯ Although preoperative cisplatin/paclitaxel with 3,000 cGy was tolerable, this multimodality regimen did not appear to be superior to standard cisplatin/5-fluorouracil-containing regimens and its use is not recommended.
-
Int. J. Radiat. Oncol. Biol. Phys. · Feb 2007
Multicenter StudyMulti-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
To assess long-term prostate-specific antigen (PSA) outcome after permanent prostate brachytherapy (BT) and identify predictors of improved disease-free survival. ⋯ Outcome after permanent BT for prostatic cancer relates to tumor stage, Gleason score, pretreatment PSA, BT year, and post-BT dosimetric quality. PSA nadir < or =0.5 ng/mL was particularly associated with durable long-term PSA disease-free survival. The only controllable factor to impact on long-term outcome was the D90 which is a reflection of implant quality.